| BackgroundSince the 20th century70-80 years, A large number of clinical trials of chemo-therapy can significantly improve survival in breast cancer patients, improve the qual-ity of life of patients after, Chemotherapy has become one of the main treatment of invasive breast cancer, Chemotherapy has become one of the main treatment of inva-sive breast cancer, but most of adjuvant chemotherapy after surgery using. Neoa-djuvant chemotherapy (neoadjuvant chemotherapy)Objective refers to the partial to give systemic chemotherapy before treatment. Then complete the systemic chemotherapy after local treatment. Initially neoadjuvant che-motherapy for locally advanced breast cancer surgery difficulties, purpose is to facili-tate the surgery after chemotherapy, tumor shrinkage, especially for some patients with unresectable, after chemotherapy can remove. So far, neoadjuvant chemotherapy has become a routine therapy for locally advanced breast cancer. With a wide range of clinical applications and in-depth research, Use of neoadjuvant chemotherapy more and more, Such as large operable breast lumps. By chemotherapy to shrink the tumor, reduce its clinical stage, so that more patients get the chance to breast-conserving therapy; It is also used to further improve the long-term neoadjuvant chemotherapy efficacy of breast cancer, also used in certain patients earlier and neoadjuvant che-motherapy and randomized study of adjuvant chemotherapy.Breast cancer is a systemic disease, In the early hematogenous prone, patients in the treatment of more than half of systemic metastasis has occurred, so the treatment should be under the control of systemic clinical lesions premise re-operation, to have the chance to more patients were cured. So the first comprehensive treatment is more reasonable for systemic chemotherapy. Studies have reported that, Preoperative chemotherapy not only can inhibit the proliferation of tumor cells, and can prevent the formation of drug-resistant cells[1]. Zhang bin, etc[2]. the operation of breast can-cer for preoperative chemotherapy and postoperative adjuvant chemotherapy control study, The results showed that, after neoadjuvant chemotherapy in patients with 5-8 years birth rate has increased significantly, long curative effect in patients also have improved.Cell proliferation is the basis of tumorigenesis, normal cells proliferation reaches a certain limit stops, and proliferation of cells was basically is equal to the number of the lost cell, the total is constant. Tumor cells are different, it is a continuous way of unlimited proliferation and the number of tumor cells are constantly increase without limit. The most prominent feature of the mechanism of tumor is the abnormal cell proliferation, how to inhibit the unlimited proliferation of tumor cells, tumor treat-ment is to consider the current problems, therefore, the study of tumor cells prolifera-tion activity, Will help to further understand the biological behavior of tumors, for the diagnosis, treatment and prognosis of tumor provide valuable indicators. The occur-rence of tumor is not only related to the abnormal proliferation and differentiation of cells, are also associated with abnormal cells apoptosis. As early as 1972 Kerr, puts forward the concept of apoptosis (apoptosis), Cell apoptosis is also called pro-grammed cell death, is controlled by genes active "suicide" of cells. Involved in regu-lating cell apoptosis cells, embryonic development and physiological processes of clone selection of the immune system, It’s in normal tissues and cells of the body to maintain homeostasis plays an important role in the If certain genetic changes lead to the change of cell apoptosis, may cause the occurrence of tumor. In the initiation and progression of breast cancer, Has confirmed that the change is not only the growth of tumor cells, the cell apoptosis has apparent change. Although many labora-tory studies have confirmed a variety of chemotherapy drugs on the role of tumor cell link is different, but all can cause the apoptosis of tumor cells, Apoptosis in cancer chemotherapy is likely to be a very important point in the process of[4,5] shows that neoadjuvant chemotherapy can induce human breast cancer cells apoptosis. Neoadju-vant chemotherapy can effectively induce tumor cell apoptosis, reduce the rate of tu- mor cell proliferation, which may make the tumor shrink, reduce or delay the transfer of tumor and improve curative effect, the new adjuvant chemotherapy for breast can-cer, which provides theoretical basis from the Angle of molecular biology.ObjectiveTo explore the new adjuvant chemotherapy for breast cancer cell cycle in G0/G1 phase cell proportion, ABCG2, CD44+CD24-/low reactivity and immunohistochemical expression the influence of related indicators.MethodSelection in our hospital in May 2013 to March 2014,60 cases treated by tubular needle biopsy definite pathological diagnosis in breast invasive ductal carcinoma treated first as the research object, compared before and after chemotherapy in breast cancer cell cycle in G0/G1 phase proportion of cells, CD44+CD24-/low content changes and the impact of immunohistochemical expression related indicators.Results1 After chemotherapy, the patients of ABCG2 (25.10+1.50)%,CD44+CD24-/low (36.40+3.80)/105 and the proportion of G0/G1 phase cells (70.50+ 1.50)% were higher than the ABCG2 before chemotherapy (15.88+1.22) %,CD44+CD24-/low (25.00+3.40)/105 and the proportion of G0/G1 phase cells (60.65+/-1.30), with significant difference (P< 0.05).2 ER, PR, before and after neoadjuvant chemotherapy CerbB-2 expression there was no significant difference (P> 0.05), the P value respectively, P= 0.501, P=0.428, P=0.693.3 K167 expression had significant difference before and after neoadjuvant chemotherapy, P=0.011<0.05.ConclusionAfter neoadjuvant chemotherapy in patients with tumor cell cycle arrest, stem cells grew, curative effect and clinical value. |
PDF Full Text Request